Intercure (INCR) - Total Assets
Based on the latest financial reports, Intercure (INCR) holds total assets worth ILA690.55 Million ILA (≈ $1.85 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore INCR operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Intercure - Total Assets Trend (2008–2025)
This chart illustrates how Intercure's total assets have evolved over time, based on quarterly financial data. See net assets of Intercure for net asset value and shareholders' equity analysis.
Intercure - Asset Composition Analysis
Current Asset Composition (December 2025)
Intercure's total assets of ILA690.55 Million consist of 45.9% current assets and 54.1% non-current assets.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 6.7% |
| Accounts Receivable | ILA154.47 Million | 22.4% |
| Inventory | ILA108.06 Million | 15.7% |
| Property, Plant & Equipment | ILA0.00 | 0.0% |
| Intangible Assets | ILA0.00 | 0.0% |
| Goodwill | ILA219.19 Million | 31.7% |
Asset Composition Trend (2008–2025)
This chart illustrates how Intercure's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Intercure (INCR) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Intercure's current assets represent 45.9% of total assets in 2025, an increase from 0.0% in 2008.
- Cash Position: Cash and equivalents constituted 6.7% of total assets in 2025, up from 0.0% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, an increase from 0.0% in 2008.
- Asset Diversification: The largest asset category is goodwill at 31.7% of total assets.
Intercure Competitors by Total Assets
Key competitors of Intercure based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Alkem Laboratories Limited
NSE:ALKEM
|
India | Rs202.87 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Alkermes plc
F:8AK
|
Germany | €4.26 Billion |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623
|
China | CN¥35.27 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
|
China | CN¥6.49 Billion |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
China | CN¥1.41 Billion |
Intercure - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.48 | 1.73 | 2.37 |
| Quick Ratio | 0.97 | 1.18 | 1.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA102.38 Million | ILA165.05 Million | ILA47.97 Million |
Intercure - Advanced Valuation Insights
This section examines the relationship between Intercure's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.43 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | -9.4% |
| Total Assets | ILA690.55 Million |
| Market Capitalization | $44.19 Million USD |
Valuation Analysis
Below Book Valuation: The market values Intercure's assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Intercure's assets decreased by 9.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Intercure (2008–2025)
The table below shows the annual total assets of Intercure from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ILA690.55 Million ≈ $1.85 Million |
-9.44% |
| 2024-12-31 | ILA762.57 Million ≈ $2.04 Million |
-3.06% |
| 2023-12-31 | ILA786.61 Million ≈ $2.11 Million |
-17.89% |
| 2022-12-31 | ILA958.01 Million ≈ $2.57 Million |
+39.59% |
| 2021-12-31 | ILA686.32 Million ≈ $1.84 Million |
+110.35% |
| 2020-12-31 | ILA326.27 Million ≈ $874.72K |
+15.60% |
| 2019-12-31 | ILA282.23 Million ≈ $756.66K |
+685.73% |
| 2018-12-31 | ILA35.92 Million ≈ $96.30K |
+50.00% |
| 2017-12-31 | ILA23.95 Million ≈ $64.20K |
-13.66% |
| 2016-12-31 | ILA27.73 Million ≈ $74.35K |
+119.75% |
| 2015-12-31 | ILA12.62 Million ≈ $33.84K |
+378.04% |
| 2014-12-31 | ILA2.64 Million ≈ $7.08K |
-57.17% |
| 2013-12-31 | ILA6.16 Million ≈ $16.53K |
-57.57% |
| 2012-12-31 | ILA14.53 Million ≈ $38.95K |
+397.71% |
| 2011-12-31 | ILA2.92 Million ≈ $7.83K |
+121.66% |
| 2010-12-31 | ILA1.32 Million ≈ $3.53K |
-40.65% |
| 2009-12-31 | ILA2.22 Million ≈ $5.95K |
-87.61% |
| 2008-12-31 | ILA17.91 Million ≈ $48.01K |
-- |
About Intercure
InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in… Read more